A phase I–II study of rituximab, ifosfamide, mitoxantrone andetoposide (R-IME) for B cell non-Hodgkin’s lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT)

Robin Joyce(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Jean-Pierre Tétreault(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Daire J. Hurley(Mater Misericordiae University Hospital), Deborah Lamontagne(Harvard University), Nancy Giallombardo(Beth Israel Deaconess Medical Center), Terry Smith(The University of Texas MD Anderson Cancer Center), T Umiel, J Levine, David F. McDermott(Beth Israel Deaconess Medical Center), J. Ottaway(Hammersmith Hospital), Meredith M. Regan(Dana-Farber Cancer Institute)
Annals of Oncology
May 1, 2003
10.1093/annonc/mdg705
Cited by 13

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k